---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-23-000106"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:07:37.285972+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Autolus voluntarily elects U.S. domestic issuer reporting, no change to Q3 2023 financials

## Summary
- Autolus will file periodic reports on Forms 10-K, 10-Q, and 8-K instead of foreign private issuer forms.
- No financial or disclosure changes from the Form 6-K filed on November 2, 2023 for the quarter ended September 30, 2023.
- Company retains foreign private issuer status, exempt from U.S. proxy rules, Regulation FD, and Section 16.
- Effective immediately; first U.S. domestic issuer report to be filed later today (Q3 2023 Form 10-Q).

## SEC filing metadata
- accession: 0001730463-23-000106
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000106/0001730463-23-000106-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046323000106/autl-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-23-000106
- JSON: https://secwatch.observer/filing/0001730463-23-000106.json
- Plain text: https://secwatch.observer/filing/0001730463-23-000106.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.